---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-23-005101"
form_type: "8-K"
ticker: "CLDX"
cik: "0000744218"
company_name: "Celldex Therapeutics, Inc."
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T03:16:32.362011+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Celldex Q2 net loss $30.5M ($0.65/sh); Phase 2 CSU enrollment complete, topline by YE 2023

## Summary
- Net loss of $30.5M ($0.65/sh) for Q2 2023 vs $36.0M ($0.77/sh) in Q2 2022; cash $252.7M.
- Phase 2 CSU enrollment completed with 208 patients, 25% above target; topline data expected by YE 2023.
- Phase 1b PN data planned for Q4 2023; Phase 2 EoE initiated, first patient dosed in July.
- R&D expenses increased to $26.3M from $20.7M YoY, driven by barzolvolimab costs.
- Cash runway sufficient through 2025 to fund planned Phase 2 studies.

## SEC filing metadata
- accession: 0001171843-23-005101
- form_type: 8-K
- ticker: CLDX
- cik: 0000744218
- company_name: Celldex Therapeutics, Inc.
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/744218/000117184323005101/0001171843-23-005101-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/744218/000117184323005101/f8k_080823.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-23-005101
- JSON: https://secwatch.observer/filing/0001171843-23-005101.json
- Plain text: https://secwatch.observer/filing/0001171843-23-005101.txt

## Key facts
- Earnings Releases
  Celldex Therapeutics, Inc. reported financial results for the second quarter ended June 30, 2023.
  - Period: the second quarter ended June 30, 2023
  - Result: reported results
  source text: On August 8, 2023, Celldex Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the second quarter of 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/744218/000117184323005101/0001171843-23-005101-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.